Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Change in Account Payables for 6 consecutive years, with -$1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 261.61% to -$1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.9 million, a 334.6% increase, with the full-year FY2024 number at $871000.0, down 2.79% from a year prior.
  • Change in Account Payables was -$1.8 million for Q3 2025 at 4D Molecular Therapeutics, down from $4.5 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.5 million in Q2 2025 to a low of -$1.8 million in Q3 2025.
  • A 5-year average of $257421.1 and a median of $226000.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 313.46% in 2022, then skyrocketed 678.75% in 2025.
  • 4D Molecular Therapeutics' Change in Account Payables stood at $1.7 million in 2021, then fell by 8.97% to $1.5 million in 2022, then plummeted by 171.91% to -$1.1 million in 2023, then soared by 234.38% to $1.5 million in 2024, then crashed by 225.65% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Change in Account Payables are -$1.8 million (Q3 2025), $4.5 million (Q2 2025), and -$235000.0 (Q1 2025).